Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amarin Seeks ITC Action Against Products 'Cloaked' As Dietary Supplements

Executive Summary

Seeking to protect its competitive interests, Vascepa marketer asks the US International Trade Commission to investigate importation and sale of synthetically produced omega-3 products by 18 companies; complaint asserts the products at issue are unapproved new drugs that are illegally being marketed as dietary supplements.

You may also be interested in...



AbbVie’s Battle Over Alvotech’s Humira Biosimilar Moves To New Ground With ITC Investigation

International Trade Commission launches investigation of adalimumab manufacturing processes in response to AbbVie complaint of misappropriation of trade secrets. District court dismissed trade secret suit on grounds it lacked jurisdiction. Trial in infringement suit is set for August.

AbbVie’s Battle Over Alvotech’s Biosimilar Humira Moves To New Ground With ITC Investigation

International Trade Commission launches investigation of adalimumab manufacturing processes in response to AbbVie complaint of misappropriation of trade secrets. District court dismissed trade secret suit on grounds it lacked jurisdiction. Trial in infringement suit is set for August.

FDA Objects To Amarin Trade Complaint Against Omega-3 Ingredients

FDA Chief Counsel Rebecca Wood says Amarin's request for an ITC investigation necessarily turns on questions of drug and supplements policy, where it is the expert and authorized agency. If successful, Amarin's move could encourage others to similarly seek alternative forums for action.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS121427

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel